Cell-Based Drug Toxicity and Efficacy Testing
Make Informed Go-No-Go Decisions Early in Your Drug Development! Process! Applied StemCell (ASC), an ISO-certified service provider offers a flexible assay platform with a wide-range of functional endpoints for early-stage in vitro screening of preclinical drug candidates. We use a comprehensive cell-based test battery from which you can choose assays for efficacy, safety or target discovery that suit your therapeutic pipeline. We will provide the scientific expertise, accurate and efficient screening to help you take informed decisions about your small/ large molecules early in your drug development process to avoid costly drug attrition. Our custom screening service is ideal for CNS, cardiovascular, metabolic, cancer, and immunotherapy drug candidates.
| Catalog ID# | Product Name | Price | ||
|---|---|---|---|---|
Brochures/ Flyers:
Posters:
1. In Vitro Disease ModelingGenome Editing/ Correction(Cancer cells, iPSCs, ESCs, primary cells) iPSC Reprogramming & Differentiation 3D Cell/ iPSC Culture |
 |
2. Drug ScreeningPhenotypic Screening Functional Validation Cell Viability/ Toxicity Mitochondrial/ Hepatic/Cardio Toxicity Customized Assay Development |
1. In Vitro Disease Modeling:
Screen your compounds in a wide-variety of cell lines! Applied StemCell is a market leader in gene editing technologies. We can engineer > 100 distinct cell lines with a wide variety of mutations, using a combination of different technologies (CRISPR/Cas9, TARGATT™ and more) and techniques (transfection/transduction) to generate many different cell line models that are perfectly suited to screen candidate compounds in your therapeutic pipeline.
- Cancer cells and cell line gene editing
- iPSC/ ESC gene editing
- Primary cell line models
- 3D cell line/ iPSC models
We also provide comprehensive iPSC services and products for iPSC-based neurotoxicity & efficacy screening:
- iPSC generation
- iPSC differentiation into tissue lineages
- iPSC and differentiated cell lines and other products
2. Drug Screening:
Flexible/ customizable project options to suit your screening needs! Below is a sample list of some of the assays we offer.
(Don’t see an assay you want? CONTACT US with your project requirements.)
|
Screening |
Types of Assays |
Estimated Timeline |
|
Cytotoxicity & Cell Viability Assays |
MTT/ MTS cell proliferation assay LDH, Necrosis and Apoptosis assays Luciferase (bioluminescence) expression cAMP level measurement |
4-6 weeks |
|
Mitochondrial Toxicity Testing |
Enzyme activity Volume fraction detection |
2-4 weeks |
|
Functional Assays |
Calcium influx/ imaging Electrophysiology: Multielectrode array (MEA) analysis and Patch clamp recording |
8-12 weeks |
|
Quantitative Gene Expression |
qPCR RNA-seq using NGS (next generation sequencing) |
2-8 weeks |
|
Morphology |
Neurite growth assay Biomarker screening |
2-4 weeks |
|
Custom Assays |
iPSC generation; characterization; gene editing; differentiation Custom assay development |
Based on project requirements |
Custom Service Project Workflow:
|
Introduction to |
- Primary point of contact during the course of the project
- Coordinates across scientific groups, and provides updates and official reports on project progress.
|
 |
|
|
Project Kick-off |
- Preliminary meeting with PM and scientists
- Ensure that objectives and expectations are aligned
|
|
|
|
Bi-weekly to Monthly |
- Regular meetings with PM and scientists
- Opportunity to communicate new data, troubleshoot challenges, and if necessary, adjust project specifications
|
|
|
|
Milestone and |
- Finalize data transfer for intermediate milestones and overall project
- Work with client to transfer final deliverables
|
